Singapore-headquartered venture capital firm Vertex Ventures has announced the launch of a $200 million Fund III through its healthcare-focused arm, Vertex Ventures HC (VVHC). VVHC, led by women, aims to support life sciences and medical technology companies at the early stages of development. The firm seeks opportunities in companies that showcase disruptive technologies, groundbreaking research, and a clear trajectory towards developing innovative medicines for patients.
Since its establishment in 2014, VVHC has managed $550 million in assets and has invested in over twenty-five companies, including nearly twenty clinical-stage assets and three products approved by the U.S. Food and Drug Administration. VVHC is backed by Vertex Holdings, a Singapore-based holding company that provides foundational funding and assistance to a global network of venture funds investing in healthcare and technology in the U.S., Israel, China, and South Asia. Notably, Vertex Venture Holdings recently raised over $900 million in the first round of fundraising for its latest fund, the Vertex Master Fund III, with a total fundraising target of $1 billion expected to be reached in the near future.